We are leveraging our proprietary ImmunoTAC™ technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections and other serious diseases.
Our ImmunoTAC™ platform combines systemic and tissue-targeted delivery, allowing us to transport disease-modifying small molecules directly to the site of a patient’s disease.
Our platform enables us to strategically pair proprietary linker-payloads that modulate key disease-modifying pathways with monoclonal antibodies directed to specific disease sites.
Antigen Binding Domain
Linker-Payload
Fc Region
We are pursuing vital pathways to unlock the potential for numerous therapeutic approaches. Our ImmunoTAC™ platform is taking us there.
We are initially applying our ImmunoTAC™ platform to create a new class of targeted immuno-oncology agents that direct a myeloid cell activator to the microenvironment in solid tumors to promote cancer cell killing.
We are initially applying our ImmunoTAC™ platform to create a new class of targeted immuno-oncology agents that direct a myeloid cell activator to the microenvironment in solid tumors to promote cancer cell killing.
Solid tumors, including those resistant to T-cell targeted immunotherapies such as PD-1 and CTLA-4 blockade, are permeated with myeloid cells. The activation and reprogramming of myeloid cells result in direct tumor killing and recruitment and activation of additional immune cells. For example, activated myeloid cells are able to amplify T-cell and natural killer (NK)-cell responses – bridging a patient’s innate and adaptive immune systems.
Successful activation of myeloid cells can lead to durable anti-tumor immunity, even in tumors that are resistant to immune checkpoint blockade. Our TLR8 agonist payload is leveraged across SBT6050, SBT6290, and SBT8230. We believe TLR8 is the optimal target for activation and reprogramming of various myeloid cell types due to its potent yet restricted expression and function within such myeloid cells.